World's Best Scientists 2026 revealed!
Massimo Galli

Massimo Galli

D-Index & Metrics

Immunology

D-Index
82
Citations
28565
World Ranking
1491
National Ranking
59

Medicine

D-Index
83
Citations
29010
World Ranking
15492
National Ranking
600

Massimo Galli publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Massimo Galli sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 625 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Massimo Galli D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Massimo Galli sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 82 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Massimo Galli is affiliated with the University of Milan in Italy and has contributed extensively to the field of medicine, with a particular focus on infectious diseases. Their scholarly output includes a significant number of publications emphasizing clinical and epidemiological aspects of COVID-19 and related viral infections.

Their main fields of study comprise Medicine, with a specific concentration in Infectious Diseases. Additional subfields of their research include Epidemiology, Neurology, Genetics, and Radiology, Nuclear Medicine and Imaging.

Research topics covered by Massimo Galli reflect a focus on various dimensions of the COVID-19 pandemic, such as:

  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19
  • COVID-19 epidemiological studies
  • SARS-CoV-2 detection and testing
  • COVID-19 diagnosis using AI
  • COVID-19 and healthcare impacts

Among the most cited recent papers associated with Massimo Galli are:

  • "Remdesivir for 5 or 10 Days in Patients with Severe Covid-19" (2020), published in the New England Journal of Medicine
  • "Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study" (2020), published in The Lancet Infectious Diseases
  • "Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study" (2020), published in Clinical Infectious Diseases
  • "Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity" (2021), published in Cell
  • "Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms" (2020), published in Science

Massimo Galli has collaborated frequently with other researchers, including:

  • Andrea Giacomelli
  • Spinello Antinori
  • Alessia Lai
  • Gianguglielmo Zehender
  • Stefano Rusconi

They have published extensively in several key venues, notably:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Vaccines
  • Clinical and Experimental Rheumatology
  • Digestive and Liver Disease
  • Journal of Medical Virology

Best Publications

  • Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.

    Jason D. Goldman;David C.B. Lye;David S. Hui;Kristen M. Marks

  • Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study.

    Andrea Giacomelli;Laura Pezzati;Federico Conti;Dario Bernacchia

  • Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.

    Luca Carsana;Aurelio Sonzogni;Ahmed Nasr;Roberta Simona Rossi

  • Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC

    Alessia Lai;Francesco Roberto Simonetti;Gaetano Brindicci;Annalisa Bergna

  • Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.

    Emma C. Thomson;Emma C. Thomson;Laura E. Rosen;James G. Shepherd;Roberto Spreafico

  • Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

    M. Alejandra Tortorici;M. Alejandra Tortorici;Martina Beltramello;Florian A. Lempp;Dora Pinto

  • COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

    Piercarlo Sarzi-Puttini;Valeria Giorgi;Silvia Sirotti;Daniela Marotto

  • A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.

    S De Vita;L Quartuccio;M Isola;C Mazzaro

  • Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.

    Laura Montefusco;Moufida Ben Nasr;Moufida Ben Nasr;Francesca D'Addio;Cristian Loretelli

  • Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

    Cristina Gervasoni;Anna Lisa Ridolfo;Giuliana Trifirò;Sara Santambrogio

  • Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias.

    G Monti;M Galli;F Invernizzi;P Pioltelli

  • Candidemia and invasive candidiasis in adults: A narrative review

    Spinello Antinori;Laura Milazzo;Salvatore Sollima;Massimo Galli

  • A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

    Katie Bechman;Sujith Subesinghe;Sam Norton;Fabiola Atzeni

  • EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.

    Robert Bm Landewé;Pedro M Machado;Féline Kroon;Hans Wj Bijlsma

  • Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.

    Sebastiano Bruno Solerte;Francesca D’Addio;Roberto Trevisan;Elisabetta Lovati

  • 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study.

    Andrea Giacomelli;Anna Lisa Ridolfo;Laura Milazzo;Letizia Oreni

  • Retinal findings in patients with COVID-19: Results from the SERPICO-19 study.

    Alessandro Invernizzi;Alessandro Invernizzi;Alessandro Torre;Salvatore Parrulli;Federico Zicarelli

  • Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.

    Maurizio Pietrogrande;Salvatore De Vita;Anna Linda Zignego;Pietro Pioltelli

  • Risk of Kaposi's Sarcoma-Associated Herpes Virus Transmission From Donor Allografts Among Italian Posttransplant Kaposi's Sarcoma Patients

    Carlo Parravicini;Sonja J. Olsen;Maria Capra;Francesca Poli

  • Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.

    Spinello Antinori;Maria Vittoria Cossu;Anna Lisa Ridolfo;Roberto Rech

  • Incidence and Characteristics of Non-Hodgkin Lymphomas in a Multicenter Case File of Patients With Hepatitis C Virus-Related Symptomatic Mixed Cryoglobulinemias

    Giuseppe Monti;Pietro Pioltelli;Francesco Saccardo;Mauro Campanini

  • Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count.

    Giulia Marchetti;Alessandro Cozzi-Lepri;Esther Merlini;Giusi M. Bellistrì

  • Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.

    François-Xavier Lescure;Hitoshi Honda;Robert A Fowler;Jennifer Sloane Lazar

  • Early phylogenetic estimate of the effective reproduction number of SARS-CoV-2.

    Alessia Lai;Annalisa Bergna;Carla Acciarri;Massimo Galli

Frequent Co-Authors

Spinello Antinori
Spinello Antinori University of Milan
Mauro Moroni
Mauro Moroni University of Milan
Adriano Lazzarin
Adriano Lazzarin Vita-Salute San Raffaele University
Claudia Balotta
Claudia Balotta University of Milan
Giuliano Rizzardini
Giuliano Rizzardini ASST Fatebenefratelli Sacco
Andrea Gori
Andrea Gori University of Milan
Cristina Mussini
Cristina Mussini University of Modena and Reggio Emilia
Mario Clerici
Mario Clerici University of Milan
Massimo Ciccozzi
Massimo Ciccozzi Università Campus Bio-Medico
Massimo Andreoni
Massimo Andreoni University of Rome Tor Vergata

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, understanding related healthcare degrees can open new career avenues. Many professionals transition into nursing through specialized programs designed to accelerate their education. For example, online ABSN programs for non nurses provide a streamlined path for individuals without a nursing background to earn a Bachelor of Science in Nursing quickly.

Similarly, there are accelerated BSN programs for non nurses that cater specifically to students eager to fast-track their nursing qualifications. These programs are often more flexible, balancing theoretical coursework with clinical experience.

For entry-level positions, exploring easy LPN programs to get into can be a practical start. Licensed Practical Nurse programs offer essential skills and certification with shorter durations, making them accessible for many.

Advancing clinical expertise is possible through nurse practitioner studies. Those curious about less demanding yet effective options often seek out what is the easiest NP program, helping them identify programs that best fit their learning style and career goals.

Best Scientists Citing Massimo Galli

Trending Scientists